Publication: Advanced therapies for the treatment of
hemophilia: future perspectives
Loading...
Official URL
Full text at PDC
Publication Date
2012-12
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
Citations
Exportar
Abstract
Monogenic diseases are ideal candidates for treatment by the emerging advanced therapies, which are capable of correcting alterations in protein expression that result from genetic mutation. In hemophilia A and B such alterations affect the activity of coagulation factors VIII and IX, respectively, and are responsible for the development of the disease. Advanced therapies may involve the replacement of a deficient gene by a healthy gene so that it generates a certain functional,structural or transport protein (gene therapy); the incorporation of a full array of healthy genes and proteins through perfusion or transplantation of healthy cells (cell therapy); or tissue transplantation and formation of healthy organs (tissue engineering). For their part, induced pluripotent stem cells have recently been shown to also play a significant role in the fields of cell therapy and tissue engineering.Hemophilia is optimally suited for advanced therapies owing to the fact that, as a monogenic condition, it does not require very high expression levels of a coagulation factor to reach moderate disease status. As a result, significant progress has been possible with respect to these kinds of strategies, especially in the fields of gene therapy (by
using viral and non-viral vectors) and cell therapy (by means of several types of target cells). Thus, although still considered a rare disorder, hemophilia is now recognized as a condition amenable to gene therapy, which can be administered in the form of lentiviral and adeno-associated vectors applied to adult stem cells, autologous fibroblasts, platelets and hematopoietic stem cells; by means of non-viral vectors; or through the repair of mutations by chimeric oligonucleotides. In hemophilia, cell therapy approaches have been based mainly on transplantation of healthy cells (adult stem cells or induced pluripotent cell-derived progenitor cells)in order to restore alterations in coagulation factor expression.
Description
UCM subjects
Unesco subjects
Keywords
Citation
1.Bolton-Maggs PHB, Pasi KJ: Haemophilias A and B. Lancet 2003, 361:1801–1809.
2.Berntorp E, Shapiro AD: Modern haemophilia care.Lancet 2012,379:1447–1456.
3.Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M:Guideline on the management of haemophilia in the fetus and neonate.Br J Haematol 2011, 154:208–215.
4.Bustamante-Aragones A, Rodriguez de Alba M, Gonzalez-Gonzalez C,Trujillo-Tiebas MJ, Diego-Alvarez D, Vallespin E, Plaza J, Ayuso C, Ramos C:Foetal sex determination in maternal blood from the seventh week ofgestation and its role in diagnosing haemophilia in the foetuses of female carriers. Haemophilia 2008, 14:593–598.
5. Lavery S: Preimplantation genetic diagnosis of haemophilia. Br J Haematol 2009, 144:303–307.
6. Liras A, Gaban AS, Rodriguez-Merchan EC: Cartilage restoration in haemophilia: advanced therapies. Haemophilia 2012, doi:10.1111/j.1365-2516.2012.02816.x.
7. Schaub RG: Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011, 82:91–98.
8. Key NS, Negrier C: Coagulation factor concentrates: past, present, and future. Lancet 2007, 370:439–448.
9. Farrugia A: Plasma fractionation issues. Biologicals 2009, 37:88–93.
10. Hermans C, Brackmann HH, Schinco P, Auerswald G: The case for wider use of recombinant factor VIII concentrates. Critical Rev Oncology/Hematology 2012,83:11–20.
11. Schulte S: Pioneering designs for recombinant coagulation factors.Thromb Res 2011, 128(Suppl 1):S9–12.
12. Batlle J, Villar A, Liras A, Alonso C, Altisent C, Brito D, Moreno M, Lucía F,Sedano C, Prieto M, Calvente N, Aznar JA, Jiménez V, Soriano V, Martorell JR,Iruín G, Bergua JM, Aguilar C: Consensus opinion for the selection and useof therapeutic products for the treatment of haemophilia in Spain. BloodCoagul Fibrinolysis 2008, 19:333–340.
13. Keeling D, Tait C, Makris M: Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2008, 14:671–684.
14. Astermark J: Inhibitor development: patient-determined risk factors. Haemophilia 2010, 16:66–70.
15. Green D: Factor VIII inhibitors: a 50-year perspective. Haemophilia 2011, 17:831–838.
16. Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernández MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K: Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010, 16:747–766.
17. Franchini M, Tagliaferri A, Mengoli C, Cruciani M: Cumulative inhibitor incidence in previously untreated patients with severe hemophilia a treated with plasma-derived versus recombinant factor VIII concentrates:a critical systematic review.CriticalRevOncology/Hematology 2012,81:82–93.
18.Mannucci PM, Mancuso ME, Santagostino E: How we choose factor VIII to treat hemophilia. Blood 2012, 119:4108–4114.
19.Andréoletti O, Litaise C, Simmons H, Corbière F, Lugan S, Costes P,Schelcher F, Vilette D, Grassi J, Lacroux C: Highly efficient prion transmission by blood transfusion. PLoS Pathog 2012, 8:e1002782. http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1002782.
20. Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW: Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010, 16:296–304.
21. Zaman SM, Hill FG, Palmer B, Millar CM, Bone A, Molesworth AM, Connor N, Lee CA, Dolan G, Wilde JT, Gill ON, Makris M: The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products.Haemophilia 2011, 17:931–937.
22.Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu JM, Subramanyam B, Fournel MA, Pierce GF, Murphy JE: Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia a treatment. Blood 2010, 116:270–279.
23. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J: Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011, 118:2695–2701.
24. Dumont JA, Liu T, Low SC, Zhang X, Kamphaus G, Sakorafas P, Fraley C, Drager D, Reidy T, McCue J, Franck HW, Merricks EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H: Prolonged activity of a recombinant factor VIII-Fc
fusion protein in hemophilia a mice and dogs. Blood 2012, 119:3024–3030.
25.Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallén B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF: Recombinant
factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012, 119:666–672.
26.Peng A, Kosloski MP, Nakamura G, Ding H, Balu-Iyer SV: PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia a mice. AAPS J 2012, 14:35–42.
27. Casademunt E, Martinelle K, Jernberg M, Winge S, Tiemeyer M, Biesert L, Knaub S, Walter O, Schröder C: The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol 2012, 89:165–176.
28.Goedert JJ, Brown DL, Hoots K, Sherman KE: Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia 2004, 10(Suppl 4):205–210.
29.Mariani E, Facchini A: Clinical applications and biosafety of human adult mesenchymal stem cells. Curr Pharm Des 2012, 18:1821–1845.
30. Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, Bellinger DA, Arruda VR, High KA: Protein replacement therapy and gene transfer in canine models of haemophilia a, haemophilia B, von willebrand disease, and factor VII deficiency. ILAR J 2009, 50:144–167.
31. Nienhuis AW: Development of gene therapy for blood disorders. Blood 2009, 111:4431–4444.
32.Liras A: Gene therapy for haemophilia: the end of a “royal pathology” in the third millennium? Haemophilia 2001, 7:441–445.
33.Liras A, Olmedillas S: Gene therapy for haemophilia. . .yes, but...with non-viral vectors? Haemophilia 2009, 15:811–816.
34.Viiala NO, Larsen SR, Rasko JE: Gene therapy for hemophilia: clinical trials and technical tribulations. Semin Thromb Hemost 2009, 35:81–92.
35.Brown BD, Cantore A, Annoni A, Sergi LS, Lombardo A, Della Valle P, D'Angelo A, Naldini L: A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007, 110:4144–4152.
36. Jeon HJ, Oh TK, Kim OH, Kim ST: Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector. Yonsei Med J 2010, 51:52–57.
37. Ramezani A, Zweier-Renn LA, Hawley RG: Factor VIII delivered by hematopoietic stem cell-derived B cells corrects the phenotype of hemophilia a mice. Thromb Haemost 2011, 105:676–687.
38. Matsui H: Endothelial progenitor cell-based therapy for hemophilia a. IntJ Hematol 2012, 95:119–124.
39. Ward NJ, Buckley SMK, Waddington SN, VandenDriessche T, Chuah MKL, Nathwani AC, McIntosh J, Tuddenham EGD, Kinnon C, Thrasher AJ, McVey JH: Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood 2011, 117:798–807.
40.Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J,Adenovirus-associated virus vector mediated gene transfer inhemophilia B. N Engl J Med 2011, 365:2357–365.
41.Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA: Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012, 119:3038–3041.
42.Montgomery RR, Shi Q: Platelet and endothelial expression of clotting factors for the treatment of hemophilia. Thromb Res 2012, 129:S46–S48.
43. Sivalingam J, Krishnan S, Ng WH, Lee SS, Phan TT, Kon OL: Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells. Mol Ther 2010, 18:1346–1356.
44. Liras A, García-Arranz M, García-Gómez I, Vega L, García-Olmo D, Olmedillas S: Factor IX secretion in human adipose-derived stem cells by non-viral gene transfer [abstract]. Haemophilia 2012, 18(Suppl 3):A65.
45.Aronovich A, Tchorsh D, Katchman H, Eventov-Friedman S, Shezen E, Martinowitz U, Blazar BR, Cohen S, Tal O, Reisner Y: Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation. Proc Natl Acad Sci USA 2006, 103:19075–19080.
46.Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S: Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia a mice. J Clin Invest 2008, 118:935–945.
47.Follenzi A, Raut S, Merlin S, Sarkar R, Gupta S: Role of bone marrow transplantation for correcting hemophilia a in mice. Blood 2012, 119:5532–5542.
48.Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, Ma Y: Phenotypic correction of murine hemophilia a using an iPSCs cell-based therapy. Proc Natl Acad Sci USA 2009, 106:808–813.
49.Yadav N, Kanjirakkuzhiyil S, Kumar S, Jain M, Halder A, Saxena R, Mukhopadhyay A: The therapeutic effect of bone marrow-derived liver cells in the phenotypic correction of murine hemophilia a. Blood 2009, 114:4552–4561.
50.Alipio Z, Adcock DM, Waner M, TM O, Fink LM, Ward DC, Ma Y: Sustained factor VIII production in hemophiliac mice 1 year after engraftment with induced pluripotent stem cell-derived factor VIII producing endothelial cells. Blood Coagul Fibrinolysis 2010, 21:502–504.
51.Gir P, Oni G, Brown SA, Mojallal A, Rohrich RJ: Human adipose stem cells: current clinical applications. Plast Reconstr Surg 2012, 129:1277–1290.